CD19-targeted CAR NK cell therapy achieves pr

<p>Researchers from <a href="http://www.MDAnderson.org">The University of Texas MD&nbsp;Anderson Cancer Center</a> reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived <a href="https://www.mdanderson.org/cancerwise/car-nk-therapy-offers-new-treatment-option-for-blood-cancers.h00-159379578.html">chimeric antigen receptor (CAR) natural killer (NK) cell therapy</a> targeting CD19. &nbsp;</p>

Related Keywords

,Katy Rezvani ,Sally Cooper Murray ,University Of Texas ,Md Anderson Moon Shots Program ,National Institutes Of Health ,Cancer Research ,Anderson Cancer Center ,Research Institute Of Texas ,Nature Medicine ,Stem Cell Transplantation ,New England Journal ,Sally Cooper Murray Endowed Chair ,National Institutes ,Cancer Prevention ,Research Institute ,Institutional Conflict ,Pinterest Management ,Monitoring Plan ,